Equities analysts forecast that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will report $9.50 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Conatus Pharmaceuticals’ earnings. The highest sales estimate is $10.10 million and the lowest is $8.72 million. Conatus Pharmaceuticals reported sales of $800,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 1,087.5%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.

On average, analysts expect that Conatus Pharmaceuticals will report full year sales of $9.50 million for the current year, with estimates ranging from $35.29 million to $36.70 million. For the next year, analysts forecast that the firm will report sales of $60.35 million per share, with estimates ranging from $39.50 million to $116.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative net margin of 80.98% and a negative return on equity of 83.02%. The company had revenue of $9.57 million for the quarter, compared to analyst estimates of $16.06 million. During the same quarter in the prior year, the company posted ($0.31) EPS.

CNAT has been the topic of several research reports. Seaport Global Securities reiterated a “buy” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $17.00 target price (down from $18.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $16.00.

Hedge funds have recently modified their holdings of the business. Voya Investment Management LLC bought a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $101,000. Wells Fargo & Company MN grew its position in Conatus Pharmaceuticals by 3,098.0% in the 3rd quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 18,588 shares in the last quarter. Bank of Montreal Can bought a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $109,000. FNY Partners Fund LP grew its position in Conatus Pharmaceuticals by 98.0% in the 2nd quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 9,800 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $115,000. 36.95% of the stock is owned by institutional investors and hedge funds.

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) traded up $0.09 during midday trading on Friday, hitting $4.01. 157,300 shares of the stock traded hands, compared to its average volume of 599,049. Conatus Pharmaceuticals has a 52-week low of $1.81 and a 52-week high of $9.40. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.41.

TRADEMARK VIOLATION WARNING: “Conatus Pharmaceuticals Inc (CNAT) Expected to Announce Quarterly Sales of $9.50 Million” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/08/conatus-pharmaceuticals-inc-cnat-expected-to-announce-quarterly-sales-of-9-50-million.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.